Tenax Therapeutics, Inc. (TENX) is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company is headquartered in Morrisville, North Carolina, USA.
Established in 2008, Tenax Therapeutics was initially known as Oxygen Biotherapeutics, which began by developing treatments for traumatic brain injuries using oxygen therapeutics. The company evolved its product pipeline and focus over the years and rebranded as Tenax Therapeutics in 2014.
One of Tenax Therapeutics' prominent drugs is Levosimendan, an in-licensed compound currently in phase 3 development for the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). Levosimendan has depicted promising results in its clinical trials, offering new hope for this difficult-to-treat patient population.
Besides Levosimendan, Tenax is also developing a selective adenosine A2A receptor antagonist for Fibrodysplasia Ossificans Progressiva, a rare, severely disabling genetic disease. The company's development approach is informed by advanced pre-clinical studies and guided by collaborations with leading investigators and key opinion leaders worldwide.
Recognized by its ticker symbol TENX on the NASDAQ, Tenax Therapeutics emphasizes transparency and shareholder value. The company routinely shares its clinical trial data, updates, and financial performances with investors and stakeholders. This open communication builds trust and assures investors that the company is on a progressive path towards advancing new treatments for cardiovascular and pulmonary diseases.
Despite potential ups and downs related to the risks inherent in high-stakes biotech drug development, Tenax remains optimistic and dedicated to its mission. Its management team, led by industry veterans with extensive experience in the drug development and commercialization arenas, continues to work diligently to bring life-saving, unmet need therapies to patients.
Tenax Therapeutics is a company created with a purpose - to provide solutions for diseases that have insufficient treatment options. It’s a firm that breeds innovation, fosters collaboration, and values scientific excellence. With an unwavering focus on research and development, TENX is striving to transform the therapy landscape for patients battling cardiovascular and pulmonary conditions.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Wall Street analysts predict a significant upside of 121.4% for Tenax Therapeutics (TENX), with a mean price target of $34.71. This optimism is supported by a positive trend in earnings estimate revisions and the company's Zacks Rank #2 (Buy) rating. Despite the potential for inflated price targets, the agreement among analysts and positive earnings revisions suggest a strong near-term upside for the stock.
Tenax Therapeutics' Independent Director, Declan Doogan, recently purchased US$102k worth of stock at US$1.92 per share, increasing his holding by 2,331%. This marks the largest insider purchase in the last year, suggesting a bullish outlook despite the company currently operating at a loss. While insider ownership remains low, the consistent buying activity indicates insiders see value in the company at its current price.
Declan Doogan, a Director at Tenax Therapeutics Inc (TENX), recently purchased 53,000 shares, increasing his total holdings to 55,274 shares. This transaction, executed at $1.92 per share, is seen as a strong vote of confidence, especially given that insiders have made 12 buys and 0 sells over the past year. The article suggests this insider activity, combined with GuruFocus's GF Value and guru ownership data, provides a bullish outlook for the clinical-stage biotechnology company.
Tenax Therapeutics (TENX) shares jumped 7.87% after the company announced a pivot in its Phase 3 strategy for TNX-103 in PH-HFpEF. While the initial broad Phase 3 trial missed its primary endpoints, a pre-specified subgroup showed statistically significant improvements, leading management to pursue an enriched LEVEL-2 Phase 3 trial focusing on this responsive subgroup. This strategic shift has led to mixed analyst sentiment, with some price target cuts but continued optimism for a registrational path in an indication with no approved therapies.
Tenax Therapeutics' Phase 3 LEVEL trial for TNX-103 in PH-HFpEF failed to meet its primary endpoint in the overall population, showing no statistically significant improvement in six-minute walk distance. However, a prespecified subgroup of patients with more severe baseline impairment showed a significant 26.3-meter improvement. The company is considering a second Phase 3 trial (LEVEL-2) with an enriched patient population, but this approach carries risks regarding regulatory approval and costs.
Tenax Therapeutics, Inc. announced that its President & Chief Executive Officer, Chris Giordano, will present at the 2026 Cantor Global Healthcare Conference on September 9, 2026. The presentation will be available via webcast on the company's investor relations webpage. Tenax Therapeutics is a Phase 3 pharmaceutical company focused on developing cardiopulmonary therapies, holding global rights to levosimendan for PH-HFpEF treatment.